title: Golimumab in unresponsive ulcerative colitis.
abstract: Ulcerative colitis (UC) is a chronic inflammation mainly affecting the colon mucosa. It predominantly occurs in younger patients. Until recently, the main goals in the treatment of UC were to temper the symptoms, such as diarrhea, pain, and weight loss, by using mesalazine and steroids. With newer medications, such as immunomodulators (thiopurines) and the biologics providing blockade of tumor necrosis factor (TNF), the goals of the therapy in UC have changed to long-term remission and mucosal healing. The first available anti-TNF therapy in UC included infusion therapy with infliximab every few weeks. In 2012, subcutaneously administered adalimumab gained approval for the treatment of UC in Germany. In patients with a mild disease, therapy with mesalazine, orally or topically, can be sufficient. In patients with moderate to severe disease, therapy with azathioprine or anti-TNF is often required to reach disease control; however, this is only efficient in about two-thirds of patients. Some patients either show no response or a lost response while on treatment. So, further medical options are warranted in the treatment of UC. With golimumab, a new approach in the treatment of mild to moderate UC recently became available in Germany and is a promising new option in the therapy regimen for patients with UC.
authors.affiliation: University Hospital Regensburg, Department of Internal Medicine I, Regensburg, Germany.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Lippert
authors.affiliation: University Hospital Regensburg, Department of Internal Medicine I, Regensburg, Germany.
authors.forename: Martina
authors.initials: M
authors.lastname: Müller
authors.affiliation: University Hospital Regensburg, Department of Internal Medicine I, Regensburg, Germany.
authors.forename: Claudia
authors.initials: C
authors.lastname: Ott
keywords: anti-TNF; biological therapy; inflammatory bowel disease